• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.

作者信息

Asai N, Iwashita T, Murakami H, Takanari H, Ohmori K, Ichihara M, Takahashi M

机构信息

Department of Pathology, Nagoya University School of Medicine, 65 Tsurumai-cho, Nagoya, Showa-ku, 466-8550, Japan.

出版信息

Biochem Biophys Res Commun. 1999 Feb 24;255(3):587-90. doi: 10.1006/bbrc.1999.0237.

DOI:10.1006/bbrc.1999.0237
PMID:10049754
Abstract

Mutations at aspartic acid 631 in Ret were reported in sporadic pheochromocytoma and medullary thyroid carcinoma. We replaced this aspartic acid with four other amino acids including tyrosine, glycine, asparagine, and alanine and investigated the transforming activity of these mutant cDNAs. Among them, RET cDNA with a mutation of aspartic acid to tyrosine (D631Y) that was reported in sporadic pheochromocytoma showed high transforming activity. The D631Y mutation activated Ret by inducing its disulfide-linked dimerization in the transfectant as observed for multiple endocrine neoplasia (MEN) 2A mutations at cysteine 609, 611, 618, 620, 630, or 634. Further mutation analysis suggested that cysteine 630 or 634 could be involved in the disulfide-linked Ret dimerization induced by the D631Y mutation.

摘要

相似文献

1
Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.
Biochem Biophys Res Commun. 1999 Feb 24;255(3):587-90. doi: 10.1006/bbrc.1999.0237.
2
Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.1995年鲁道夫·魏尔啸奖。RET原癌基因突变分析在2型多发性内分泌腺瘤病(MEN 2)基因携带者诊断以及散发性和家族性甲状腺髓样癌与嗜铬细胞瘤鉴别中的作用
Verh Dtsch Ges Pathol. 1995;79:L-LV.
3
[Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].通过检测RET原癌基因突变携带者对2型多发性内分泌肿瘤(MEN 2)进行早期诊断
Medicina (B Aires). 1998;58(2):179-84.
4
Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.2B型多发性内分泌腺瘤及相关散发性肿瘤中RET原癌基因酪氨酸激酶结构域内的点突变。
Hum Mol Genet. 1994 Feb;3(2):237-41. doi: 10.1093/hmg/3.2.237.
5
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.2A型多发性内分泌腺瘤病中RET原癌基因的种系突变。
Nature. 1993 Jun 3;363(6428):458-60. doi: 10.1038/363458a0.
6
Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A.
J Clin Endocrinol Metab. 1994 Aug;79(2):590-4. doi: 10.1210/jcem.79.2.7913936.
7
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.RET原癌基因的突变与2A型多发性内分泌腺瘤病和家族性甲状腺髓样癌相关。
Hum Mol Genet. 1993 Jul;2(7):851-6. doi: 10.1093/hmg/2.7.851.
8
Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.多发性内分泌腺瘤病2A突变激活ret原癌基因的机制。
Mol Cell Biol. 1995 Mar;15(3):1613-9. doi: 10.1128/MCB.15.3.1613.
9
A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene.一例与RET原癌基因两个新发突变相关的2A型多发性内分泌腺瘤病的新病例。
J Clin Endocrinol Metab. 1999 Oct;84(10):3522-7. doi: 10.1210/jcem.84.10.6056.
10
Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.表达具有2A型多发性内分泌肿瘤突变的RET原癌基因的转基因小鼠中的组织特异性致癌作用。
Cancer Res. 2000 Sep 15;60(18):5254-60.

引用本文的文献

1
Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).RET D631Y 变体多发性内分泌肿瘤 2 型(MEN2)的临床特征和信号转导效应。
Korean J Intern Med. 2022 Mar;37(2):398-410. doi: 10.3904/kjim.2021.311. Epub 2021 Dec 15.
2
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.针对 RET 驱动型癌症:不断发展的临床前和临床领域的经验教训。
Nat Rev Clin Oncol. 2018 Mar;15(3):151-167. doi: 10.1038/nrclinonc.2017.175. Epub 2017 Nov 14.
3
Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury.
神经营养因子及其受体在周围神经损伤后的轴突再生和功能恢复中的作用
Mol Neurobiol. 2003 Jun;27(3):277-324. doi: 10.1385/MN:27:3:277.